CDK4 and cancer: Second, several compounds against the CCND1 associated cyclin-dependent kinase CDK4 are currently under investigation in clinical phase I-II trials in multiple cancer types, including an open-label phase I study on advanced solid cancers (NCT01188252) assessing of the impact of CCND1 amplification and expression on therapy efficacy.